Literature DB >> 20071483

Establishment and application of an infectious virus-like particle system for Marburg virus.

Jörg Wenigenrath1, Larissa Kolesnikova, Thomas Hoenen, Eva Mittler, Stephan Becker.   

Abstract

The highly pathogenic Marburg virus (MARV) can only be investigated in high containment laboratories, which is time consuming and expensive. To investigate the MARV life cycle under normal laboratory conditions, an infectious virus-like particle (VLP) system was developed. The infectious VLP system is based on the T7-polymerase driven synthesis of a MARV-specific minigenome that encodes luciferase and is transcribed and replicated by the simultaneously expressed MARV nucleocapsid proteins NP, VP35, L and VP30. Transcription of the minigenome resulted in luciferase activity and replication resulted in encapsidated minigenomes. The encapsidated minigenomes, together with the viral matrix proteins VP40 and VP24 and the surface glycoprotein (GP), formed VLPs at the plasma membrane. Among the released pleomorphic VLPs, filamentous particles of 200-400 nm in length showed the highest capacity to induce reporter activity upon infection of target cells. To characterize the infectious VLP system, the intracellular concentration of one of the components was titrated, while all others were held constant. Intracellular concentrations of nucleocapsid proteins that resulted in highest replication and transcription activities also yielded VLPs with the highest ability to induce luciferase activity in target cells. High intracellular levels of VP40 maximized the release of VLPs, but reduced their ability to induce luciferase activity in target cells. The intracellular concentration of GP positively correlated with its incorporation into VLPs and their infectivity. Finally, we demonstrated that the infectious VLP system was suitable for rapid screening of neutralizing antibodies directed against MARV.

Mesh:

Substances:

Year:  2010        PMID: 20071483     DOI: 10.1099/vir.0.018226-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  32 in total

1.  Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Authors:  Gopi S Mohan; Ling Ye; Wenfang Li; Ana Monteiro; Xiaoqian Lin; Bishu Sapkota; Brian P Pollack; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Viral and host proteins that modulate filovirus budding.

Authors:  Yuliang Liu; Ronald N Harty
Journal:  Future Virol       Date:  2010-07-01       Impact factor: 1.831

3.  Tsg101 is recruited by a late domain of the nucleocapsid protein to support budding of Marburg virus-like particles.

Authors:  Olga Dolnik; Larissa Kolesnikova; Lea Stevermann; Stephan Becker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances.

Authors:  Gordian Schudt; Larissa Kolesnikova; Olga Dolnik; Beate Sodeik; Stephan Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

5.  RNA Binding of Ebola Virus VP30 Is Essential for Activating Viral Transcription.

Authors:  Nadine Biedenkopf; Julia Schlereth; Arnold Grünweller; Stephan Becker; Roland K Hartmann
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

6.  The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection.

Authors:  Eva Mittler; Larissa Kolesnikova; Bettina Hartlieb; Robert Davey; Stephan Becker
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

7.  A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus.

Authors:  Stephanie Devignot; Eric Bergeron; Stuart Nichol; Ali Mirazimi; Friedemann Weber
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

8.  Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection.

Authors:  Verena Krähling; Olga Dolnik; Larissa Kolesnikova; Jonas Schmidt-Chanasit; Ingo Jordan; Volker Sandig; Stephan Günther; Stephan Becker
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity.

Authors:  Ari Watt; Felicien Moukambi; Logan Banadyga; Allison Groseth; Julie Callison; Astrid Herwig; Hideki Ebihara; Heinz Feldmann; Thomas Hoenen
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.